Efficacy and Safety of Pirfenidone for Mitigation of Interstitial Lung Abnormalities in COVID-19 Patients: A Meta-Analysis

Ítems similars

• South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
  per: Shaney L. Barratt, et al.
  Publicat: (2018-12-01)
• Pirfenidone for the treatment of interstitial lung disease associated to rheumatoid arthritis: a new scenario is coming?
  per: Giulia Cassone, et al.
  Publicat: (2020-01-01)
• Bibliometric analysis of the pirfenidone and nintedanib in interstitial lung diseases
  per: Jia Liu, et al.
  Publicat: (2024-04-01)
• Spectrum of autoantibodies and other serological parameters in connective tissue disease–associated interstitial lung disease patients
  per: Pooja Jaiswal, et al.
  Publicat: (2026-06-01)
• Evaluation of the efficacy of pirfenidone in progressive chronic hypersensitivity pneumonitis
  per: Eman Shebl, et al.
  Publicat: (2021-03-01)